Masashi Kondo

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 895 citations

Medicine, Randomised Phase 3, Pathology +8

Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression

David G. Burbee, Éva Forgács, Sabine Zöchbauer‐Müller et al. · JNCI Journal of the National Cancer Institute · 2001 · 769 citations · Full text

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer · 2017 · 232 citations · Full text

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 231 citations · Full text

Open-label Trial, Late Favipiravir Therapy, Clinical Infectious Disease +14

Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers.

Masashi Kondo, Hidenori Suzuki, Ryuzo Ueda et al. · PubMed · 1995 · 211 citations